Fifty One Capital updated report, page-19

In the short term there is a lot to be excited about. 

Potential Share Price Catalysts / NewsflowThere is potential for significant news flow in the 1-12 months

 OA Phase 2b trial results released – mid/late December 2018

 Further release of up to 50 patients OA data under the TGA special access scheme (by end ofCY18) 

Progression of the newly in-licensed MPS indication

 Ross River Phase 2a trial results release – Q1CY2019

 Dose first Compassionate Use OA patient in the US

 Potential for significant media attention assuming successful treatment of high profile NFL players (past and present)

 Finalise and announce recruitment of US based staff

 File IND and meet with FDA around Phase 3 trial in OA/BMEL

 Possibility of being granted “fast track status” for the Phase 3 trial

 Possibility of early revenue in 2019 via receiving ‘Provisional Approval’ from TGA to sell Zilosul (iPPS)

 Upcoming release of peer review scientific paper/s